As a reminder I have zero experience in oncology To my understanding HER-Vaxx was never designed or intended to be a standalone treatment, rather meant to be coupled with SoC to improve efficacy with minimal toxicity. The results from HORIZON showed improved OS for those treated with HER-Vaxx combination therapy vs. SoC only. An 80% CI is just fine in clinical trials, especially Phase 2. It's simply a lever to pull to help expedite trial recruitment as a smaller sample size is needed vs. a study powered at 95%. If IMU has confidence that their drug shows promise and is willing to play it a bit riskier in the clinic by utilizing a smaller sample size and CI, then so be it. That is their gamble to take.
Side note, it would be nice to have links to all the studies/data you're posting.
- Forums
- ASX - By Stock
- IMU
- Why IMU is a multi multi bagger
Why IMU is a multi multi bagger, page-25090
-
- There are more pages in this discussion • 1,368 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMU (ASX) to my watchlist
(20min delay)
|
|||||
Last
5.1¢ |
Change
0.003(6.25%) |
Mkt cap ! $379.2M |
Open | High | Low | Value | Volume |
4.9¢ | 5.5¢ | 4.8¢ | $4.098M | 80.11M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 1984777 | 5.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.2¢ | 450000 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 1984777 | 0.051 |
26 | 4357226 | 0.050 |
28 | 4638765 | 0.049 |
25 | 3754138 | 0.048 |
28 | 2095851 | 0.047 |
Price($) | Vol. | No. |
---|---|---|
0.052 | 450000 | 3 |
0.053 | 769607 | 7 |
0.054 | 1377917 | 8 |
0.055 | 6018397 | 11 |
0.056 | 1630609 | 15 |
Last trade - 16.10pm 18/09/2024 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |